Protalix (PLX) - מכפיל P/S עתידי

The expected revenue multiple reflects market optimism, with the 8.00 figure serving as the target level for Protalix BioTherapeutics (PLX). Growth is driven by the implementation of ProCellEx automated bioreactors, which eliminate defects. The strategy relies on the joint development of drugs with major partners. Independence from macroeconomic trends makes this sector a defensive asset, ensuring a steady flow of capital into innovations for treating rare pathologies.

A conservative investor assesses the fundamental value of Protalix BioTherapeutics (PLX) through the lens of potential future cash flow capitalization. The expected P/S multiple relates the current market value of the business to projected revenue, which allows this chart to determine the extent of the overpayment for the unique capacities of the Israeli protein expression plant and evaluate the sustainability of the control premium over the assets.